Chang-Keun Kim, Zak Callaway, Jin-Sung Park, Ruby Pawankar, Takao Fujisawa
{"title":"Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation.","authors":"Chang-Keun Kim, Zak Callaway, Jin-Sung Park, Ruby Pawankar, Takao Fujisawa","doi":"10.5415/apallergy.0000000000000129","DOIUrl":null,"url":null,"abstract":"<p><p>Asthma and allergic rhinitis (AR) are 2 of the most common chronic inflammatory disorders and they appear to be on the rise. Current pharmacotherapy effectively controls symptoms but does not alter the underlying pathophysiology. Allergen immunotherapy (AIT) is an evidence-based therapy for asthma and AR and has been recognized as the only therapeutic method that actually modifies the allergic disease process. There is a lack of objective markers that accurately and reliably reflect the therapeutic benefits of AIT. A biomarker indicating patients that would benefit most from AIT would be invaluable. Eosinophilic inflammation is a cardinal feature of many allergic diseases. Biomarkers that accurately reflect this inflammation are needed to better diagnose, treat, and monitor patients with allergic disorders. This review examines the current literature regarding AIT's effects on eosinophilic inflammation and biomarkers that may be used to determine the extent of these effects.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"32-38"},"PeriodicalIF":1.6000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932480/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.0000000000000129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Asthma and allergic rhinitis (AR) are 2 of the most common chronic inflammatory disorders and they appear to be on the rise. Current pharmacotherapy effectively controls symptoms but does not alter the underlying pathophysiology. Allergen immunotherapy (AIT) is an evidence-based therapy for asthma and AR and has been recognized as the only therapeutic method that actually modifies the allergic disease process. There is a lack of objective markers that accurately and reliably reflect the therapeutic benefits of AIT. A biomarker indicating patients that would benefit most from AIT would be invaluable. Eosinophilic inflammation is a cardinal feature of many allergic diseases. Biomarkers that accurately reflect this inflammation are needed to better diagnose, treat, and monitor patients with allergic disorders. This review examines the current literature regarding AIT's effects on eosinophilic inflammation and biomarkers that may be used to determine the extent of these effects.
哮喘和过敏性鼻炎（AR）是两种最常见的慢性炎症性疾病，而且似乎呈上升趋势。目前的药物疗法能有效控制症状，但无法改变潜在的病理生理学。过敏原免疫疗法（AIT）是治疗哮喘和过敏性鼻炎的一种循证疗法，被认为是唯一能真正改变过敏性疾病过程的治疗方法。目前还缺乏能准确可靠地反映过敏原免疫疗法治疗效果的客观标志物。如果能找到一种生物标志物来指示哪些患者能从 AIT 中获益最多，那将是非常宝贵的。嗜酸性粒细胞炎症是许多过敏性疾病的主要特征。为了更好地诊断、治疗和监测过敏性疾病患者，需要能准确反映这种炎症的生物标志物。本综述研究了有关 AIT 对嗜酸性粒细胞炎症的影响以及可用于确定这些影响程度的生物标志物的现有文献。
期刊介绍：
Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
